See more : TPG Telecom Limited (TPG.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Tevogen Bio Holdings Inc. (TVGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tevogen Bio Holdings Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Sumitomo Osaka Cement Co., Ltd. (SUCEF) Income Statement Analysis – Financial Results
- Ventoux CCM Acquisition Corp. (VTAQ) Income Statement Analysis – Financial Results
- Integrated Diagnostics Holdings plc (IDGXF) Income Statement Analysis – Financial Results
- FTAC Hera Acquisition Corp. (HERA) Income Statement Analysis – Financial Results
- Banners Co., Ltd. (3011.T) Income Statement Analysis – Financial Results
Tevogen Bio Holdings Inc. (TVGN)
About Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 5.77M | 2.96M |
| General & Administrative | 2.27M | 953.08K | 1.66M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 2.27M | 953.08K | 1.66M |
| Other Expenses | 0.00 | -7.38M | -10.38M |
| Operating Expenses | 2.27M | 953.08K | 4.62M |
| Cost & Expenses | 2.27M | 953.08K | 4.62M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 256.03K | 0.00 | 598.50K |
| Depreciation & Amortization | 197.55K | 230.82K | 9.38K |
| EBITDA | 188.71K | -953.08K | -28.75K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.84K | -13.72M | -4.62M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -58.48K | 4.42M | -15.59M |
| Income Before Tax | -67.33K | 4.41M | -15.60M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -230.82K | -9.78M |
| Net Income | -67.33K | 4.41M | -15.60M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.04 | -0.13 |
| EPS Diluted | 0.00 | 0.04 | -0.13 |
| Weighted Avg Shares Out | 165.42M | 120.00M | 120.00M |
| Weighted Avg Shares Out (Dil) | 165.42M | 120.00M | 120.00M |
Tevogen Bio Announces $8 Million Equity Investment
Source: https://incomestatements.info
Category: Stock Reports